Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer.

ABSTRACT:

Background

Head and neck squamous cell cancer (HNSCC) frequently causes severe symptoms that may be reduced, when the tumor is successfully treated. The SOCCER trial studied the association of treatment response with patient reported tumor symptom burden in first line treatment of recurrent and/or metastatic HNSCC.

Methods

In this prospective, multi-center, non-interventional trial patients were treated either with platinum-based chemotherapy and cetuximab or radiotherapy and cetuximab. Tumor symptom burden was assessed every four weeks with a questionnaire containing ten visual analogue scales (VAS, range 0-100), which were summarized to the overall VAS score.

Results

Fourhundred seventy patients were registered in 97 German centers. A total of 315 patients with at l

SUBMITTER: Hecht M 

PROVIDER: S-EPMC7526421 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature